Optimal management strategies for primary HPV testing for cervical screening: Cost-effectiveness evaluation for the national cervical screening program in Australia

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Simms, Kate T ^a,b,g   Hall, Michaela ^a,b,g   Smith, Megan A ^a,b,c,g   Lew, Jie Bin ^a,b,g   Hughes, Suzanne ^a   Yuill, Susan ^a   Hammond, Ian ^d,e   Saville, Marion ^f,g   Canfell, Karen ^a,b,c,g  

^a CANCER RESEARCH DIVISION   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Steering Committee for the Renewal Implementation Project   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f VICTORIAN CYTOLOGY SERVICE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CANCER IMMUNIZATION; CANCER RISK; CANCER SCREENING; CHILD; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; FEMALE; FOLLOW UP; HEALTH PROGRAM; HISTORY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; PROSPECTIVE STUDY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; COST BENEFIT ANALYSIS; CYTODIAGNOSIS; DISEASE MANAGEMENT; EARLY CANCER DIAGNOSIS; ECONOMICS; EVALUATION STUDY; GENETICS; GENOTYPE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PUBLIC HEALTH; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

VIRUS DNA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHILD; COLPOSCOPY; COST-BENEFIT ANALYSIS; CYTODIAGNOSIS; DISEASE MANAGEMENT; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 85009796992     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0163509     Document Type: Article

References (71)

1. Rijksinstituut voor Volksgezondheid en Milieu (2014) Population screening will change (in Dutch). Bilthoven, the Netherlands
2. National Screening Unit (2016) Primary HPV testing consultation.
3. Wise J (2012) Pilot study will assess whether HPV test should replace smears to screen for cervical cancer. BMJ 344: e3744. doi: 10.1136/bmj.e3744 PMID: 22641810
4. Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, , et al. (2014) Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383: 524-532. doi: 10.1016/S0140-6736(13)62218-7 PMID: 24192252
5. Canfell K (2015) The Australian Example: An Integrated Approach To HPV Vaccination And Cervical Screening. HPV Today. 34 ed.
6. Castle PE, Glass AG, Rush BB, Scott DR, Wentzensen N, , et al. (2012) Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol 30: 3044-3050. doi: 10.1200/JCO.2011.38.8389 PMID: 22851570
7. Gage JC, Duggan MA, Nation JG, Gao S, Castle PE (2013) Comparative Risk of High-Grade Histopathology Diagnosis After a CIN 1 Finding in Endocervical Curettage Versus Cervical Biopsy. J Low Genit Tract Dis.
8. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, , et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J NatlCancer Inst 97: 1072-1079.
9. National HPV Vaccination Program Register (2015) HPV Vaccination Coverage Data.
10. Brotherton JML, Liu B, Donovan B, Kaldor JM, Saville M (2014) Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 32: 592-597. doi: 10.1016/j.vaccine. 2013.11.075 PMID: 24316239
11. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, , et al. (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15: 565-580. doi: 10.1016/S1473-3099(14)71073-4 PMID: 25744474
12. Australian Institute of Health and Welfare (2014) Cervical screening in Australia 2011-2012. Cancer series no.82. Cat. no. CAN 79. Canberra: AIHW, .
13. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, , et al. (2015) Fall in genital warts diagnoses in the general and Indigenous Australian population following a national HPV vaccination program: analysis of routinely collected national hospital data. J Infect Dis 211: 91-99. doi: 10.1093/infdis/jiu370 PMID: 25117753
14. Harrison C, Britt H, Garland S, Conway L, Stein A, , et al. (2014) Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS ONE 9.
15. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, , et al. (2014) Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat crosssectional study. Lancet Infect Dis 14: 958-966. doi: 10.1016/S1473-3099(14)70841-2 PMID: 25107680
16. Osborne SL, Tabrizi SN, Brotherton JM, Cornall AM, Wark JD, , et al. (2015) Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. Vaccine 33: 201-208. doi: 10.1016/j.vaccine.2014.10.045 PMID: 25444787
17. Ali H, Donovan B, Wand H, Read TR, Regan DG, , et al. (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346: f2032. doi: 10.1136/bmj.f2032 PMID: 23599298
18. Brotherton JM, Gertig DM, May C, Chappell G, Saville M (2016) HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust 204: 184-184e181. PMID: 26985843
19. Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV (2008) The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 123: 1854-1863. doi: 10.1002/ijc.23633 PMID: 18636563
20. Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, , et al. (2011) The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine 29: 9112-9122. doi: 10.1016/j.vaccine.2011.02.091 PMID: 21419773
21. Medical Services Advisory Committee (2013) National Cervical Screening Program Renewal: Evidence Review (Assessment Report). MSAC Application No. 1276. Canberra: Australian Government Department of Health.
22. Lew JB, Simms K, Smith MA, Kang YK, Xu XM, , et al. (2014) National Cervical Screening Program Renewal: Effectiveness modelling and economic evaluation in the Australian setting. MSAC application number 1276 assessment report. Canberra: Department of Health.
23. Cancer Council Australia Cervical Cancer Prevention Guidelines Working Party (2016) Draft clinical management guidelines for the prevention of cervical cancer. Sydney: Cancer Council Australia.
24. Programmes NHSCS (2011) NHS Cervical Screening Programme: About Cervical Screening.
25. National Screening Unit (2008) Guidelines for Cervical Screening in New Zealand: Incorporating the management of women with abnormal cervical smears. Wellington: National Screening Unit, Ministry of Health.
26. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, , et al. (2012) Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344: e670. doi: 10.1136/bmj.e670 PMID: 22391612
27. Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ (2008) Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination. J Natl Cancer Inst 100: 308-320. doi: 10.1093/jnci/djn019 PMID: 18314477
28. Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, , et al. (2014) The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess 18: 1-196.
29. Lew J-B, Simms K, Smith M, Lewis H, Neal H, , et al. (2016) Effectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand. PLoS ONE 11: e0151619. doi: 10.1371/journal.pone.0151619 PMID: 27187495
30. Castle PE, Stoler MH, Wright TC Jr., Sharma A, Wright TL, , et al. (2011) Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12: 880-890. doi: 10.1016/S1470-2045(11)70188-7 PMID: 21865084
31. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr., , et al. (2012) Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol.
32. Chatzistamatiou K, Moysiadis T, Moschaki V, Panteleris N, Agorastos T (2016) Comparison of cytology, HPV DNA testing and HPV 16/18 genotyping alone or combined targeting to the more balanced methodology for cervical cancer screening. Gynecologic oncology.
33. Ebisch RM, de Kuyper-de Ridder GM, Bosgraaf RP, Massuger LF, IntHout J, , et al. (2016) The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples. International journal of cancer 139: 691-699. doi: 10.1002/ijc.30090 PMID: 26991464
34. Simms KT, Laprise J-F, Smith MA, Lew J-B, Caruana M, , et al. (2016) Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. The Lancet Public Health 1: e66-e75.
35. Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, , et al. (2016) Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine Results for four developed countries. Int J Cancer 139: 2771-2780. doi: 10.1002/ijc.30392 PMID: 27541596
36. Canfell K, Sitas F, Beral V (2006) Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust 185: 482-486. PMID: 17137451
37. Creighton P, Lew J, Clements M, Smith M, Howard K, , et al. (2010) Cervical cancer screening in Australia: modelled evaluation of the impact of changing the recommended interval from two to three years. BMC Public Health 10: 734. doi: 10.1186/1471-2458-10-734 PMID: 21110881
38. Canfell K, Barnabas R, Patnick J, Beral V (2004) The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 91: 530-536. doi: 10.1038/sj.bjc. 6602002 PMID: 15266332
39. Canfell K, Clements M, Harris J (2008) Cost-effectiveness of proposed changes to the national cervical screening program.
40. Canfell K, Lew JB, Smith M, Walker R (2011) Cost-effectiveness modelling beyond MAVARIC study end-points. In: Kitchener HC, Blanks R, Cubie H, Desai M, Dunn G, et al., editors. MAVARICa comparison of automation-assisted and manual cervical screening: a randomised controlled trial Health Technology Assessment 2011; Vol 15: No 3.
41. Medical Services Advisory Committee (2009) Automation Assisted and Liquid Based Cytology for Cervical Cancer Screening. MSAC reference 1122, Assessment report. Canberra: Australian Government Department of Health.
42. Medical Services Advisory Committee (2009) Human Papillomavirus Triage Test For Women With Possible or Definite Low-Grade Squamous Intraepithelial Lesions. MSAC reference 39, Assessment report. Canberra: Australian Government Department of Health.
43. Legood R, Smith MA, Lew JB, Walker R, Moss S, , et al. (2012) Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS Sentinel Sites Study. BMJ 345.
44. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, , et al. (2011) Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 29: 2487-2494. doi: 10. 1016/j.vaccine.2010.12.085 PMID: 21211586
45. Shi JF, Canfell K, Lew JB, Zhao FH, Legood R, , et al. (2011) Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer 11: 239. doi: 10.1186/1471-2407-11-239 PMID: 21668946
46. Australian Institute of Health and Welfare (AIHW) (2011) ACIM (Australian Cancer Incidence and Mortality) Books; AIHW, editor. Canberra.
47. Australian Bureau of Statistics (2012) Deaths, Australia, 2011. Canberra: ABS.
48. Australian Bureau of S (2002) National Health Survey, Summary of Results, Australia, 2001. Canberra: ABS.
49. Kang YJ (2012) Patterns of care study and development of a mode of treatment, survival and mortality for invasive cervical cancer: The University of Sydney.
50. Smith MA, Canfell K (2014) Testing previous model predictions against new data on human papillomavirus vaccination program outcomes. BMC Res Notes 7: 109. doi: 10.1186/1756-0500-7-109 PMID: 24568634
51. Council DoHaAae (January, 2003) Guidelines for Economic Evaluation of Environmental Health Planning and Assessment. http://www.health.gov.au/internet/main/publishing.nsf/Content/91C3DED41716F10DCA257BF0001E35A5/$File/eee-guides1.pdf.
52. Rodriguez-Carunchio L, Soveral I, Steenbergen RD, Torne A, Martinez S, , et al. (2015) HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG 122: 119-127. doi: 10.1111/1471-0528.13071 PMID: 25229645
53. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, , et al. (2012) Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30 Suppl 5: F88-99.
54. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, , et al. (2008) Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstetrics & Gynecology 111: 167-177.
55. Davey E, d'Assuncao J, Irwig L, Macaskill P, Chan SF, , et al. (2007) Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 335: 31. doi: 10.1136/bmj.39219.645475.55 PMID: 17604301
56. Australian Institute of Health and Welfare A (2012) ACIM (Australian Cancer Incidence and Mortality) Books. Canberra: AIHW.
57. Medical Services Advisory Committee (2014) MSAC Outcomes Public Summary Document: Application No. 1276-Renewal of the National Cervical Screening Program. Canberra: Australian Goverment Department of Health.
58. National Health and Medical Research Council (2005) Screening to Prevent Cervical Cancer: Guidelines for the Management of Asymptomatic Women with Screen Detected Abnormalities. Canberra: Commonwealth of Australia.
59. Baandrup L, Munk C, Andersen KK, Junge J, Iftner T, , et al. (2012) HPV16 is associated with younger age in women with cervical intraepithelial neoplasia grade 2 and 3. Gynecol Oncol 124: 281-285. doi: 10.1016/j.ygyno.2011.10.020 PMID: 22036987
60. Brotherton JM, Tabrizi SN, Garland SM (2012) Does HPV type 16 or 18 prevalence in cervical intraepithelial neoplasia grade 3 lesions vary by age An important issue for postvaccination surveillance. Future Microbiol 7: 193-199. doi: 10.2217/fmb.11.161 PMID: 22324989
61. Simonella L, Lewis H, Smith M, Neal H, Bromhead C, , et al. (2013) The prevalence of type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect Dis 13.
62. Howell-Jones R, Bailey A, Beddows S, Sargent A, de SN, , et al. (2010) Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer 103: 209-216. doi: 10.1038/sj.bjc.6605747 PMID: 20628396
63. Australian Bureau of Statistics (2013) 3222.0 Population Projections Australia, 2012 (base) to 2101 (Series B). 26/11/2013 ed. Canberra
64. Gertig D, Smith M, Kang YJ, Canfell K, Saville M (2013) Analysis of compliance with NHMRC 2006 Guidelines in: Report on monitoring activities of the National Cervical Screening Program Safety Monitoring Committee. Cancer series 80. Cat. no. CAN 77. Canberra.
65. Elfgren K, Rylander E, Rådberg T, Strander B, Strand A, , et al. (2005) Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. American journal of obstetrics and gynecology 193: 650-657. doi: 10.1016/j. ajog.2005.01.056 PMID: 16150255
66. Kjñr SK, Frederiksen K, Munk C, Iftner T (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. Journal of the National Cancer Institute 102: 1478-1488. doi: 10.1093/jnci/djq356 PMID: 20841605
67. Budd AC, Brotherton JM, Gertig DM, Chau T, Drennan KT, , et al. (2014) Cervical screening rates for women vaccinated against human papillomavirus. Med J Aust 201: 279-282. PMID: 25163380
68. Whop LJ, Garvey G, Baade P, Cunningham J, Lokuge K, , et al. (2016) The first comprehensive report on Indigenous Australian women's inequalities in cervical screening: A retrospective registry cohort study in Queensland, Australia (2000-2011). Cancer 122: 1560-1569. doi: 10.1002/cncr.29954 PMID: 27149550
69. Aminisani N, Armstrong BK, Canfell K (2012) Cervical cancer screening in Middle Eastern and Asian migrants to Australia: a record linkage study. Cancer Epidemiol 36: e394-400. doi: 10.1016/j.canep. 2012.08.009 PMID: 23017217
70. Cuzick J, Wheeler C (2016) Need for expanded HPV genotyping for screening. Papillomavirus Research.
71. Smith MA, Gertig D, Hall M, Simms K, Lew J-B, , et al. (2016) Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use. BMC health services research 16: 1.